{"id":"W2907895732","doi":"10.3324/haematol.2018.205948","title":"Gemtuzumab ozogamicin in acute myeloid leukemia: act 2, with perhaps more to come","year":2018,"lang":"en","type":"editorial","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Gemtuzumab ozogamicin; Myeloid leukemia; Calicheamicin; Medicine; Leukemia; Oncology; Internal medicine; CD33; Biology; Genetics; Stem cell","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.0008649051,0.001180613,0.003133982,0.001130872,0.0002070694,0.000117984,0.001349904,0.002914754,0.001020236],"category_scores_gemma":[0.001973177,0.0008202629,0.0002970335,0.001347479,0.0007133721,0.0001543169,0.0008476549,0.004480217,0.002086046],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004813927,"about_ca_system_score_gemma":0.004820596,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005265118,"about_ca_topic_score_gemma":0.0003583471,"domain_scores_codex":[0.9925669,0.0002517168,0.00104368,0.001928371,0.002415735,0.001793564],"domain_scores_gemma":[0.9949275,0.001020313,0.0003800264,0.002019238,0.0008696097,0.0007833617],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.005829018,0.000150395,0.0007020312,0.0007473897,0.0004232682,0.01284845,0.0005382675,0.000002790724,0.0001780862,0.00003568681,0.9779478,0.000596856],"study_design_scores_gemma":[0.006294743,0.005017527,0.001510242,0.001923045,0.0004780984,0.00161719,0.0003676143,0.00006865124,0.0005707173,0.00005128366,0.9809766,0.001124226],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"editorial","genre_gemma":"editorial","genre_scores_codex":[0.3686375,0.0007953639,0.0001612696,0.009204883,0.5739288,0.009480243,0.0009421172,0.001201551,0.03564833],"genre_scores_gemma":[0.0222101,0.001323948,0.007974071,0.002140801,0.9354142,0.001085999,0.002724887,0.0006003196,0.02652568],"genre_candidate":"editorial","genre_consensus":"editorial","teacher_disagreement_score":0.3614855,"threshold_uncertainty_score":0.999893,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01562678945501358,"score_gpt":0.3132534552288764,"score_spread":0.2976266657738629,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}